about
Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonanceT1 mapping and survival in systemic light-chain amyloidosis.Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy.Extracellular volume quantification in isolated hypertension - changes at the detectable limits?Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMRNormal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLIMyocardial T1 mapping.Automatic Measurement of the Myocardial Interstitium: Synthetic Extracellular Volume Quantification Without Hematocrit Sampling.Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study.Native T1 mapping in transthyretin amyloidosis.T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique.Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping.Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study.Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease.Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis".AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology.Assessment of the interstitial volume in healthy volunteers. An equilibrium contrast CMR study.LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study.Single breath-hold Vd(m) calculation as good as multi breath-hold technique in Equilibrium Contrast CMR.An instantaneous ECV with no blood sampling: using native blood T1 for hematocrit is as good as standard ECV.CMR findings in high endurance veteran athletes - a 247 subject study.Response by Merghani et al to Letters Regarding Article, "Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes With a Low Atherosclerotic Risk Profile".Clinical recommendations of cardiac magnetic resonance, Part I: ischemic and valvular heart disease: a position paper of the working group 'Applicazioni della Risonanza Magnetica' of the Italian Society of Cardiology.Does Sport Participation Worsen the Clinical Course of Hypertrophic Cardiomyopathy? Clinical Outcome of Hypertrophic Cardiomyopathy in Athletes.CMR detects a reduction in infarct size and myocardial edema when primary PCI is augmented by Remote Ischemic Conditioning. A randomized trial.Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis - a 2 year follow-up study.A simple technique to measure TAPSE and MAPSE on CMR and normal values.Multiorgan ECV as measured by EQ-MRI in systemic amyloidosisGlobal extracellular volume (ECVglobal) in HCM - the "next generation" test for risk in hypertrophic cardiomyopathy?T1 mapping for myocardial extracellular volume measurement by cardiovascular magnetic resonance: bolus only vs primed infusion techniqueAge and gender dependence of pre-contrast T1-relaxation times in normal human myocardium at 1.5T using ShMOLLIPre-contrast ShMOLLI T1 mapping in cardiac AL amyloidosisCardiac involvement in cardiac AL amyloidosis as measured by equilibrium contrast cardiovascular magnetic resonanceInterstitial expansion in health and disease - an equilibrium contrast CMR studyA new variant of apical hypertrophic cardiomyopathy? T wave inversion and relative but not absolute apical left ventricular hypertrophyDiffuse interstitial fibrosis in well-controlled hypertensionVariable myocardial interstitial expansion by T1 mapping within LGE area in infarction and hypertrophic cardiomyopathyCMR detects abnormal septal convexity into the left ventricle in preclinical hypertrophic cardiomyopathyMyocardial iron quantification using T2* and native T1mapping - a 250 patient study
P50
Q30423465-C6A81182-051D-4593-9973-2926391804C0Q34994098-A3D81563-7D69-42DD-9747-C0829655C453Q35899352-4843A368-B9A0-4025-9F7E-462B36509A17Q35945674-0BCFC50D-7594-49E9-BDB9-9A13ABF90A99Q36165179-CA8B6E66-EC55-4B24-A870-22204A3823B3Q36555952-F361FA11-42D0-4984-B401-BACF697C4B6BQ36722640-C203E4DD-5791-42F4-836D-9E25BE939706Q38369121-902639D7-6B01-44C0-ABD8-14D58B83BFF8Q38418247-79582183-1705-42D1-B09F-12BF1034A152Q38425844-8CD535B7-C8C8-48D2-970E-92D156492EB6Q38442488-2B653AB8-B3F0-4746-A233-1A0B01A97708Q38451361-184D4E2E-333E-47C1-9D65-913B4B834CC0Q38451576-C0AD03A6-788D-4A5C-9AB6-B43C05B0A21CQ38456041-B2476CE1-32CB-4244-AB3B-A29282321A13Q38458867-15E61EDF-C9A3-48B4-984F-256262E85F72Q42936212-8F6CDB05-4086-4706-B685-2BCD07B3FD4AQ45778969-11521E44-58D6-4B05-A342-E80CE2A1B1A9Q46123785-0B2F14CB-EBE2-430A-8214-300BCA48129EQ46412107-852E8545-1095-4A22-83E9-8FB393A5713CQ46478019-702CF005-E371-4172-89BA-BFB302C0E848Q46718385-D65DAF28-FDC0-4692-9B01-8AFF9D8C7474Q46737436-B33754DE-F4DB-47E6-B067-B2EA5438D60EQ47644984-DD4B8B29-6AE3-4D0A-8790-5198F84A2F6AQ48001580-A9BA8EB2-9F9A-41A1-A9C4-16A78D16176CQ49598359-64464F3F-F3E9-4EA4-B5C5-78AD993443BDQ55536545-AC486DA5-F8FD-4B86-9A4A-86447E5B8519Q55541343-3B867416-040F-4ADF-8758-4269C92ED298Q55543276-53E5B08A-A7DC-4D90-8E97-C9F1A9C501B9Q57943395-7A93FD97-DF69-475D-B9B2-735F24DAFC1FQ58008769-60F86C64-8CE5-4FC7-AED2-AA6FA91CD3BEQ58008776-FF5C4B28-7C0F-4EF4-8A19-7EF61E87F39BQ58008798-73858632-6E9B-452F-AB98-61186C0918F6Q58008805-555D7385-79CC-46E1-901C-09133B09A615Q59291570-3A8E8C66-C9BA-4649-8AEF-72CF022CEC16Q59291593-F39D7F3D-DF87-449C-B178-B7BEF54977D0Q59304232-D2C5A664-553C-4E39-9412-05B61F8986EEQ59304257-36D9F19D-5E77-497C-84BA-0009EF67F46AQ59304271-5CD226DC-AB8E-44B1-BDFE-32156CC4CCB3Q59403322-FB3E0ABA-C753-42D9-8EB4-0DF313DDEB27Q59410470-83623F28-BF6B-4643-BCA2-415A6899CF3C
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Viviana Maestrini
@ast
Viviana Maestrini
@en
Viviana Maestrini
@es
Viviana Maestrini
@nl
type
label
Viviana Maestrini
@ast
Viviana Maestrini
@en
Viviana Maestrini
@es
Viviana Maestrini
@nl
prefLabel
Viviana Maestrini
@ast
Viviana Maestrini
@en
Viviana Maestrini
@es
Viviana Maestrini
@nl
P31
P496
0000-0002-3225-8378